PSTX poseida.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
The price history of Poseida Therapeutics (PSTX) demonstrates an EV/EBITDA ratio of . The business relies on the implementation of the piggyBac system to create safe, non-viral CAR-T therapies. The development of innovative treatments for oncology and hereditary disorders is combined with partnerships to minimize costs. The high authority of management and long-term relationships with pharmaceutical leaders guarantee the sustainable development of scientific projects.
poseida.com (PSTX) - פילוחי מדדים ודוחות פיננסיים
The scientific authority of Poseida Therapeutics (PSTX) leadership and their strategic R&D alliances establish a foundation for stable capitalization. By analyzing this EV/EBITDA multiple chart, an investor assesses the company's value relative to its operating profit, excluding the impact of the tax regime and debt structure. This indicator's price action allows for the identification of asset consolidation phases and confirms the resilience of market value amid the development of new drugs.
